Drug Trial Radar · NCT00523965
Combination Therapy in Indian Visceral Leishmaniasis
Last checked: Nov 19, 2026Latest source record: May 26, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
624
Planned (sponsor's estimate)
Start
Sep 2007
Primary completion
Aug 2009
Study completion Feb 2010
Sponsor
- Lead sponsor
- Banaras Hindu UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Drugs for Neglected Diseases; Rajendra Memorial Research Institute of Medical Sciences
- First posted
- Sep 3, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Rationale The overall objective of this trial is to identify a safe and effective combination, (co-administration) short course treatment for the treatment of VL which could be easily deployed in a control programme. The hypothesis is that the combination treatment is as effective or better than the 5 mg/kg single dose of AmBisome and will reduce the risk of parasite resistance occurring. Safety and tolerability should be such that the combination can be easily deployed. Objective The specific primary and secondary objectives are as follows: Primary objective: To identify a short course combination treatment regimen which is at least as effective as a single dose of AmBisome 5mg/kg Secondary objective: To compare safety and tolerability of the various treatments measured by vital signs, blood biochemistry, (renal and liver function tests) haematology, spontaneous and elicited adverse event reporting Primary Endpoint: The primary efficacy endpoint variable is parasitological clearance 2 weeks after start of treatment with no relapse during follow up and no clinical signs or symptoms of VL at 6 months post treatment. Parasitology is only carried out at any time during follow-up or at six months post treatment if there are signs or symptoms of VL infection.
Conditions
- Leishmaniasis, Visceral
Interventions
amphotericin B deoxycholateDrug
Amphotericin B deoxycholate 1 mg/kg on alternate days for 15 infusions
Liposomal Amphotericin B with MiltefosineDrug
Liposomal Amphotericin B 5 mg Miltefosine 50 mg twice daily if patient weighs equal to or \> 25 kg Miltefosine 50 mg once daily if patient weighs \<25 mg
Liposomal Amphotericin B and Paromomycin SulfateDrug
AmBisome 5mg/kg iv infusion over 2 h x 1 day (single dose) + paromomycin sulfate 15 mg/kg/day i.m for 10 days, on day 2-11
miltefosine + Paromomycin sulfateDrug
oral miltefosine 50mg once daily (\< 25 kg body weight) or twice daily ( \> 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 10 days + Paromomycin sulfate 15 mg/kg/day im. for 10 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Final cure at six month follow upTime frame: 18 months
- Cure at six month follow upTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kala-azar Medical Research Center
Muzaffarpur, Bihar, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.